Beyond Air, Inc. (XAIR) · Oct 8, 2026 · Earnings
In line — Preliminary revenue $2.3M; 2026 guide reaffirmed at $8M
Beyond Air’s preliminary earnings show accelerating LungFit PH revenue, yet the company makes no change to its 2026 or 2027 guidance.
Beyond Air is in the early commercial scale-up of its cylinder-free LungFit PH nitric-oxide system, with hospital adoption and international distribution expanding while the second-generation system remains dependent on FDA approval. Its prior quarter release described the business as preparing for a larger commercial phase, supported by financing, broader hospital access and a pending PMA supplement.
The installed business is growing at a credible pace. Preliminary revenue reached approximately $2.3 million, up 30% sequentially from the quarter ended June 30, 2026 and 27% year over year. 〔0〕 That supports the claim that the first-generation LungFit PH is gaining traction, rather than the quarter being driven only by future FDA hopes.
| Metric | Current | Comparison / expectation |
|---|---|---|
| Preliminary quarterly revenue | $2.3M | +30% sequentially; +27% year over year |
| Calendar 2026 revenue guidance | $8M | Reaffirmed; excludes second-generation LungFit PH |
| Calendar 2027 revenue guidance | $16M–$18M | Reaffirmed; assumes second-generation system revenue, pending FDA approval |
The result is encouraging, but not a guidance inflection. The company reaffirmed its $8 million 2026 revenue target and its $16 million–$18 million 2027 target, rather than raising either outlook. With no reliable published quarterly consensus available, the cleanest benchmark is the company’s own prior outlook: this reads as execution in line with the existing plan, not a fresh upside reset.
The larger growth case still rests on an FDA decision. The second-generation LungFit PH remains under review, and 2027 guidance includes its anticipated revenue only if approval arrives. 〔1〕 The filing therefore strengthens the current commercial base but does not remove the key regulatory dependency behind the next step-up in revenue.
Bottom line: Beyond Air is showing real sequential commercial momentum, but this filing advances the existing story rather than changing it. The business is progressing toward its targets; the larger revenue opportunity still depends on second-generation FDA approval.
Complete Q3 results, November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!